Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin

This study aimed to clarify that organic anion transporters (OATs) mediate the drug–drug interaction (DDI) between imipenem and cilastatin. After co-administration with imipenem, the plasma concentrations and the plasma concentration-time curve (AUC) of cilastatin were significantly increased, while...

Full description

Bibliographic Details
Main Authors:	Yanna Zhu, Xiaokui Huo, Changyuan Wang, Qiang Meng, Zhihao Liu, Huijun Sun, Aiping Tan, Xiaodong Ma, Jinyong Peng, Kexin Liu
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	Asian Journal of Pharmaceutical Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S1818087618306342

Similar Items

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
by: Xiaokui Huo, et al.
Published: (2019-09-01)

Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp
by: Huan Jin, et al.
Published: (2020-05-01)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
by: Maria Agudelo, et al.
Published: (2019-01-01)

Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through inhibition of organic anion transporter 1/3 in rats
by: Shilei Yang, et al.
Published: (2019-11-01)

The Pattern of Imipenem/Cilastatin Administration in Imam Khomeini Hospital (Ardabil) in 2018
by: Moien Zakavati, et al.
Published: (2019-04-01)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
by: Kabbara WK, et al.
Published: (2015-03-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
by: Mona I. Shaaban, et al.
Published: (2017-04-01)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
by: Islam M Ghazi, et al.
Published: (2020-01-01)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
by: Islam M Ghazi, et al.
Published: (2020-01-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
by: Alex A. Erasmo
Published: (2004-07-01)

Treatment of Ventilator-Associated Gram-Negative Pneumonia with Imipenem-Cilastatin/Amikacin Versus Ticarcillin-Clavulanate/Amikacin
by: Ahmet ELALDI, et al.
Published: (2006-06-01)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
by: Chang-Hua Chen, et al.

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation
by: C Kani, et al.
Published: (2005-06-01)

A Prospective Randomized Trial of Imipenem-Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra-Abdominal and Pelvic Infections
by: Lionel A Mandell, et al.
Published: (1993-01-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation
by: Kani C., et al.
Published: (2005-07-01)

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection
by: A. K. Chaudhary, et al.
Published: (2010-01-01)

Retrospective evaluation of piperacillin–tazobactam, imipenem–cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia
by: Eman Youssif, et al.
Published: (2018-07-01)

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
by: Chen Xiaoping, et al.
Published: (2010-07-01)

A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve.
by: Le Zou, et al.
Published: (2019-01-01)

Resveratrol enhances the protective effects of JBP485 against indomethacin-induced rat intestinal damage in vivo and vitro through up-regulating oligopeptide transporter 1 (Pept1)
by: Rong Shu, et al.
Published: (2019-03-01)

Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells
by: Wei Liu, et al.
Published: (2018-11-01)

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China
by: Chen Y, et al.
Published: (2018-11-01)

Kidney-Protector Lipidic Cilastatin Derivatives as Structure-Directing Agents for the Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery
by: Samuel Martinez-Erro, et al.
Published: (2021-07-01)

Adenine: an important drug scaffold for the design of antiviral agents
by: Changyuan Wang, et al.
Published: (2015-09-01)

Drug Utilization Evaluation of Imipenem in Patients Undergoing Bone Marrow Transplantation
by: Elnaz Sakhaiyan, et al.
Published: (2009-04-01)

Drug Utilization Evaluation of Imipenem in Patients Undergoing Bone Marrow Transplantation
by: Elnaz Sakhaiyan, et al.
Published: (2009-06-01)

Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity
by: Blanca Humanes, et al.
Published: (2015-01-01)

Lipid imaging for visualizing cilastatin amelioration of cisplatin-induced nephrotoxicity
by: Estefanía Moreno-Gordaliza, et al.
Published: (2018-09-01)

Drug evaluation is also a clinical activity
by: Eduardo López-Briz, et al.
Published: (2021-01-01)

Catalpol-Induced AMPK Activation Alleviates Cisplatin-Induced Nephrotoxicity through the Mitochondrial-Dependent Pathway without Compromising Its Anticancer Properties
by: Jiangnan Zhang, et al.
Published: (2021-01-01)

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]
by: Babinchak Timothy, et al.
Published: (2005-10-01)

ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ANIONIC COMPONENTS IN THE DIET AND HERBAL MEDICINES ON ORGANIC ANION TRANSPORTERS (SLC22 FAMILY)
by: Wang, Li
Published: (2013)

Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy
by: Matilde Zaballos, et al.
Published: (2021-01-01)

Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study.
by: Aiping Wen, et al.
Published: (2016-01-01)

Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4
by: Chenchang Liu, et al.
Published: (2019-01-01)

The Efficacy of AgNO3 Nanoparticles Alone and Conjugated with Imipenem for Combating Extensively Drug-Resistant Pseudomonas aeruginosa
by: Shahbandeh M, et al.
Published: (2020-09-01)

Pharmacokinetic Studies ofDrug-Drug Interactions by Renal Organic Anion Transporter Iin Rabbits
by: Yun-An Chen, et al.
Published: (2009)

P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug–herb/drug–drug interactions
by: Liang S, et al.
Published: (2014-05-01)

Upstream region of OprD mutations in imipenem-resistant and imipenem-sensitive Pseudomonas isolates
by: Masoumeh Kiani, et al.
Published: (2021-06-01)

Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties
by: Kang Luo, et al.
Published: (2019-06-01)